In this capacity, the consultant will 1) receive and clarify information from NIIMBL pertaining to the “industry needs”, 2) identify “solutions” and published evidence which address the needs, 3) analyze “need / solution pairs” using a interoperability conceptual framework to document gaps and challenges, 4) document and deliver solution challenges, and gaps findings to the Big-Data Program / Interoperability Workstream within the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
In this capacity, the consultant will 1) receive information from NIIMBL members pertaining to the “industry needs”, 2) identify “solutions” with published evidence which address the needs, 3) analyze “need / solution pairs” using a interoperability conceptual framework to document gaps and challenges, 4) document and deliver solution(s), challenges, and gaps findings to the Big-Data Program / Interoperability Workstream within the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).
This initiative maximizes ROI by eliminating the high costs of redundant development, potentially reducing engineering overhead by 20–30% and ensuring industry members leverage existing global standards rather than investing in expensive, custom-built data silos.
By resolving interoperability gaps now, our accelerated technology transfers by up to 40% and improve speed-to-market by 3–6 months through seamless, standardized data exchange across our global manufacturing network.
Ultimately, this project provides the foundational architecture required to scale high-value AI and Big Data analytics, transforming raw bioprocessing information into a streamlined enterprise asset that can drive a 15–25% increase in operational throughput.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Agilent
Boehringer Ingelheim
EMD Millipore Corporation
North Carolina State University
Pfizer, Inc.